vs
AIM ImmunoTech Inc.（AIM）与EXELIXIS, INC.（EXEL）财务数据对比。点击上方公司名可切换其他公司
EXELIXIS, INC.的季度营收约是AIM ImmunoTech Inc.的28507.8倍（$598.7M vs $21.0K）。EXELIXIS, INC.净利率更高（40.8% vs -19881.0%，领先19921.8%）。EXELIXIS, INC.同比增速更快（5.6% vs -53.3%）。过去两年EXELIXIS, INC.的营收复合增速更高（18.7% vs -27.5%）
AIM ImmunoTech是一家总部位于美国佛罗里达州奥卡拉的生物制药企业，前身是Hemispherx Biopharma，1990年成立，目前专注于研发用于治疗多种癌症、各类病毒感染以及免疫缺陷疾病的创新疗法。
Exelixis是一家总部位于美国加利福尼亚州阿拉米达的基因组学药物研发企业，专注于创新抗肿瘤药物开发，旗下产品Cometriq已获美国FDA批准用于治疗甲状腺髓样癌，在其余多种转移性癌症治疗领域也已展现出良好临床活性。
AIM vs EXEL — 直观对比
营收规模更大
EXEL
是对方的28507.8倍
$21.0K
营收增速更快
EXEL
高出59.0%
-53.3%
净利率更高
EXEL
高出19921.8%
-19881.0%
两年增速更快
EXEL
近两年复合增速
-27.5%
损益表 — Q4 2025 vs Q4 2026
| 指标 | | |
|---|---|---|
| 营收 | $21.0K | $598.7M |
| 净利润 | $-4.2M | $244.5M |
| 毛利率 | — | 95.6% |
| 营业利润率 | -14057.1% | 39.3% |
| 净利率 | -19881.0% | 40.8% |
| 营收同比 | -53.3% | 5.6% |
| 净利润同比 | 30.0% | 74.8% |
| 每股收益（稀释后） | $-6.46 | $0.89 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AIMEXEL
| Q1 26 | — | $598.7M | ||
| Q4 25 | $21.0K | $597.8M | ||
| Q3 25 | $26.0K | $568.3M | ||
| Q2 25 | $25.0K | $555.4M | ||
| Q1 25 | $16.0K | $566.8M | ||
| Q4 24 | $45.0K | — | ||
| Q3 24 | $35.0K | $539.5M | ||
| Q2 24 | $50.0K | $637.2M |
净利润AIMEXEL
| Q1 26 | — | $244.5M | ||
| Q4 25 | $-4.2M | $193.6M | ||
| Q3 25 | $-3.3M | $184.8M | ||
| Q2 25 | $-2.8M | $159.6M | ||
| Q1 25 | $-3.7M | $139.9M | ||
| Q4 24 | $-6.0M | — | ||
| Q3 24 | $-3.7M | $118.0M | ||
| Q2 24 | $-1.8M | $226.1M |
毛利率AIMEXEL
| Q1 26 | — | 95.6% | ||
| Q4 25 | — | 96.9% | ||
| Q3 25 | — | 96.6% | ||
| Q2 25 | — | 96.5% | ||
| Q1 25 | — | 96.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 96.8% | ||
| Q2 24 | — | 97.2% |
营业利润率AIMEXEL
| Q1 26 | — | 39.3% | ||
| Q4 25 | -14057.1% | 39.6% | ||
| Q3 25 | -9411.5% | 37.6% | ||
| Q2 25 | -10584.0% | 33.6% | ||
| Q1 25 | -22618.8% | 28.8% | ||
| Q4 24 | -13011.1% | — | ||
| Q3 24 | -12825.7% | 25.2% | ||
| Q2 24 | -7388.0% | 43.3% |
净利率AIMEXEL
| Q1 26 | — | 40.8% | ||
| Q4 25 | -19881.0% | 32.4% | ||
| Q3 25 | -12630.8% | 32.5% | ||
| Q2 25 | -11176.0% | 28.7% | ||
| Q1 25 | -23156.3% | 24.7% | ||
| Q4 24 | -13260.0% | — | ||
| Q3 24 | -10571.4% | 21.9% | ||
| Q2 24 | -3672.0% | 35.5% |
每股收益（稀释后）AIMEXEL
| Q1 26 | — | $0.89 | ||
| Q4 25 | $-6.46 | $0.69 | ||
| Q3 25 | $1.57 | $0.65 | ||
| Q2 25 | $-3.68 | $0.55 | ||
| Q1 25 | $-0.05 | $0.47 | ||
| Q4 24 | $-21.80 | — | ||
| Q3 24 | $-6.00 | $0.40 | ||
| Q2 24 | $-3.00 | $0.77 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $1.1B |
| 总债务越低越好 | $4.5M | — |
| 股东权益账面价值 | $-9.8M | $2.2B |
| 总资产 | $5.8M | $2.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AIMEXEL
| Q1 26 | — | $1.1B | ||
| Q4 25 | $3.0M | $988.5M | ||
| Q3 25 | $2.4M | $791.1M | ||
| Q2 25 | $835.0K | $1.0B | ||
| Q1 25 | $2.2M | $1.1B | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | $7.2M | $1.2B | ||
| Q2 24 | $10.1M | $1.0B |
总债务AIMEXEL
| Q1 26 | — | — | ||
| Q4 25 | $4.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $3.3M | — |
股东权益AIMEXEL
| Q1 26 | — | $2.2B | ||
| Q4 25 | $-9.8M | $2.2B | ||
| Q3 25 | $-6.1M | $2.0B | ||
| Q2 25 | $-6.5M | $2.1B | ||
| Q1 25 | $-3.9M | $2.2B | ||
| Q4 24 | $-1.3M | — | ||
| Q3 24 | $2.9M | $2.3B | ||
| Q2 24 | $6.1M | $2.1B |
总资产AIMEXEL
| Q1 26 | — | $2.8B | ||
| Q4 25 | $5.8M | $2.8B | ||
| Q3 25 | $5.5M | $2.7B | ||
| Q2 25 | $4.1M | $2.8B | ||
| Q1 25 | $6.2M | $2.9B | ||
| Q4 24 | $8.6M | — | ||
| Q3 24 | $13.6M | $3.0B | ||
| Q2 24 | $15.7M | $2.8B |
负债/权益比AIMEXEL
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.0M | $333.5M |
| 自由现金流经营现金流 - 资本支出 | — | $332.4M |
| 自由现金流率自由现金流/营收 | — | 55.5% |
| 资本支出强度资本支出/营收 | — | 0.2% |
| 现金转化率经营现金流/净利润 | — | 1.36× |
| 过去12个月自由现金流最近4个季度 | — | $875.8M |
8季度趋势，按日历期对齐
经营现金流AIMEXEL
| Q1 26 | — | $333.5M | ||
| Q4 25 | $-2.0M | $290.3M | ||
| Q3 25 | $-5.1M | $49.0M | ||
| Q2 25 | $-1.5M | $211.4M | ||
| Q1 25 | $-2.4M | $240.3M | ||
| Q4 24 | $-4.0M | — | ||
| Q3 24 | $-3.1M | $271.3M | ||
| Q2 24 | $-3.0M | $119.5M |
自由现金流AIMEXEL
| Q1 26 | — | $332.4M | ||
| Q4 25 | — | $288.8M | ||
| Q3 25 | — | $46.2M | ||
| Q2 25 | — | $208.5M | ||
| Q1 25 | — | $236.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $263.1M | ||
| Q2 24 | — | $113.0M |
自由现金流率AIMEXEL
| Q1 26 | — | 55.5% | ||
| Q4 25 | — | 48.3% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | — | 37.5% | ||
| Q1 25 | — | 41.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 17.7% |
资本支出强度AIMEXEL
| Q1 26 | — | 0.2% | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 1.0% |
现金转化率AIMEXEL
| Q1 26 | — | 1.36× | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | — | 1.72× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.30× | ||
| Q2 24 | — | 0.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
